We've ceased enrolment & dosing in the $CHM CDH17 Phase 1 study following a second dose-limiting toxicity at Dose Level 3. Anti-tumour activity observed supports CDH17 as a valid target for further development, with a focus on an in vivo approach.
https://t.co/bTHHnSVhpL
Our CEO, Rebecca McQualter, presented at last week’s TechKnow Invest Roadshow held in Melbourne & Sydney. A recording of the presentation is now available.
View Rebecca’s presentation here: https://t.co/zaZJPhcSuU
#CHM#Biotech#CellTherapy#ClinicalTrials#TechKnow2026#ASX
We've received $1.62M advance on our FY2026 R&D tax incentive. The funding will support our ongoing Phase 1/2 clinical trial activities and general working capital as we continue our previously announced Strategic Review.
https://t.co/xv4YY9Eul8
Yesterday, our CEO Dr Rebecca McQualter presented at the Melbourne TechKnow 2026 Roadshow, providing an update on $CHM's clinical-stage cell therapy portfolio, including our CDH17 CAR-T Phase 1/2 trial and CORE-NK platform. We look forward to presenting in Sydney tomorrow.
We're looking forward to attending the TechKnow Invest Roadshow in Melbourne and Sydney on 27 & 29 July, where our CEO, Dr Rebecca McQualter, will present an update on Chimeric Therapeutics.
Monday, 27 July 2026
2:30pm, Sydney
Wednesday, 29 July 2026
9:00am, Melbourne
$CHM
We've treated 4 patients at the highest dose, Dose Level 3, in our ongoing Phase 1/2 clinical trial of $CHM CDH17. New preliminary data from 2 patients shows encouraging anti-tumour activity, including tumour shrinkage of 17% to 40% in individual lesions.
https://t.co/RjZ0HrnIjD
Our CEO Dr Rebecca McQualter will be speaking at ISCT ANZ 2026 in Melbourne as part of the Commercial Workstream session, "Capital Raising to FIH to Path to Commercialisation."
Tuesday, 21 July, 4:45pm to 5:45pm.
Learn more: https://t.co/vhMFDWRZzW
#ISCTANZ2026 $CHM
We're proud to announce that $CHM has been recognised with the Regional Leadership Award – CGT Company of the Year (Australia & New Zealand) at the Asia-Pacific CGT Excellence Awards 2026.
Thank you to the organisers & congratulations to all of this year's finalists and winners.
This Bowel Cancer Awareness Month, we recognise the impact of bowel cancer across Australia. @Chimeric is advancing $CHM CDH17, a CAR T-cell therapy being investigated in colorectal & other gastrointestinal cancers. We're focused on developing new treatment options for patients.
We've achieved 82% stable disease per RECIST, with 9 of 11 evaluable patients achieving stable disease. $CHM CDH17 expanded & persisted in all treated patients, with evidence of disease control in heavily pre-treated metastatic cancer patients.
https://t.co/V5AZN49T1d
We’re in Philadelphia visiting Minaris for a closer look at a manufacturing run for $CHM CDH17. CEO Dr Rebecca McQualter and Head of Manufacturing Dr Agathe Bourgogne visited the site as CHM CDH17 progresses through Phase 1/2 clinical development in gastrointestinal cancers.
We’ve achieved 60% CR/CRi in the ADVENT-AML NCT05834244 Phase 1B clinical trial, with 25 patients enrolled, 60% have demonstrated complete responses. High risk, frontline patients are being treated with CHM CORE-NK + standard of care.
https://t.co/CgO3smprx9
$CHM #Biotech
Our CEO Dr Rebecca McQualter, will join industry leaders in #Rome this month to moderate “From Phase 1 to BLA: Early Decisions that Impact Global Expansion” on 29 April, 11:30am CET.
The panel includes leaders from Autolus Therapeutics, Cabaletta Bio and Cellares. $CHM